{"protocolSection": {"identificationModule": {"nctId": "NCT00346398", "orgStudyIdInfo": {"id": "DAIT ITN025AD"}, "organization": {"fullName": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "briefTitle": "Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study", "officialTitle": "A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)", "acronym": "GPAC"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-05"}, "primaryCompletionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-06-27", "studyFirstSubmitQcDate": "2006-06-27", "studyFirstPostDateStruct": {"date": "2006-06-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-08-29", "resultsFirstSubmitQcDate": "2013-12-13", "resultsFirstPostDateStruct": {"date": "2013-12-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-03-29", "lastUpdatePostDateStruct": {"date": "2017-05-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Allergy and Infectious Diseases (NIAID)", "class": "NIH"}, "collaborators": [{"name": "Immune Tolerance Network (ITN)", "class": "NETWORK"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.", "detailedDescription": "Researchers suspect that allergies to common inhaled allergens (such as house dust mite, cat dander, and grass pollens) are a major cause of childhood asthma. Recent evidence suggests that if allergies to inhaled allergens are prevented, this can cause changes in the immune system that may inhibit the development of asthma. Although strategies to prevent allergies generally focus on avoiding the allergen, complete avoidance of the common allergens linked to asthma would require extreme measures and is impractical.\n\nOral mucosal immunoprophylaxis (OMIP) therapy is an allergy treatment that can induce long-lasting immune tolerance in people already suffering from allergies. By exposing the patient to small, repeated, but increasing doses of the problem allergen over a long period of time, the patient's immune system is eventually desensitized to that particular allergen. OMIP therapy has been shown to be safe in children as young as 2 years old. This study will evaluate if OMIP therapy against common inhaled allergens is safe and effective in preventing the development of asthma in children at high risk for developing the disease. Children enrolled in this study have been diagnosed with eczema or food allergies and have a family history of eczema, allergic rhinitis, or asthma.\n\nThere are two groups in this study. The experimental arm participants will receive OMIP therapy (a mixture of house dust mite, cat, and timothy grass allergens) as daily oral drops under the tongue for 1 year; Placebo arm participants will receive an allergen free placebo solution. Participants will be followed for an additional 3 years to see whether they develop allergies or asthma and to determine how OMIP affects their immune system's response to allergens. There will be 5 study visits in the first year and 6 visits over the next 3 years. At all visits, participants will be assessed for allergy/asthma symptoms, will be asked to complete questionnaires, and may be asked to provide blood or saliva samples."}, "conditionsModule": {"conditions": ["Asthma", "Allergic Sensitization"], "keywords": ["asthma", "allergen", "allergic disease", "allergen immunotherapy", "allergic sensitization", "atopic dermatitis", "eczema", "food allergy", "oral mucosal immunoprophylaxis (OMIP)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 51, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Oral mucosal immunoprophylaxis (OMIP)", "type": "EXPERIMENTAL", "description": "Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.", "interventionNames": ["Biological: Oral mucosal immunoprophylaxis (OMIP)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Oral mucosal immunoprophylaxis (OMIP)", "description": "OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.", "armGroupLabels": ["Oral mucosal immunoprophylaxis (OMIP)"], "otherNames": ["Allergen immunotherapy"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion", "description": "Allergic sensitization is defined as a positive serum allergen specific Immunoglobulin E (IgE) CAP test\\[1\\] or a positive allergy skin prick test\\[2\\]. Not experiencing allergic sensitization is the better outcome for this measure.\n\n1. A positive serum allergen specific IgE CAP (ImmunoCAP) test result is defined by a result \\>= 0.35 kU/L. Higher scores indicate greater allergic sensitization.\n2. A positive skin prick test is defined as a wheal diameter that is 3 mm larger than that produced by a negative control. Higher wheal sizes indicate greater allergic reaction or sensitization.", "timeFrame": "Three years (36 months) after Treatment Completion"}], "secondaryOutcomes": [{"measure": "Number of Participants With Current Asthma at Month 36 Status Post Treatment Completion", "description": "Participants who currently have asthma three years after end of treatment. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze. Current asthma is defined as a diagnosis of asthma and at least one episode of wheeze lasting 3 or more consecutive days in the past 12 months.", "timeFrame": "Three years (36 months) after Treatment Completion"}, {"measure": "Time to First Onset of Asthma", "description": "Time to first onset of asthma is the time from the day a participant is randomized and initiates study treatment to the diagnosis of the first of three episodes of asthma. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze.", "timeFrame": "From Treatment Initiation to Month 36 Status Post Treatment Completion"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with eczema (atopic dermatitis)\n* Family history of eczema, allergic rhinitis, or asthma\n* Allergy to one or more of the following: egg white, cow's milk, peanut, or soybean\n* Weigh at least 9.5 kg (20.9 lbs)\n* Parent or guardian willing to provide informed consent\n\nExclusion Criteria:\n\n* Allergy to house dust mite, cat, or timothy grass\n* Born prematurely (before 36th week's gestation)\n* Previous diagnosis of asthma OR have had 3 or more distinct episodes of wheeze during the first year of life\n* Chronic pulmonary disease\n* Chronic disease requiring therapy\n* Past or current treatment with systemic immunomodulator medication\n* Past or current treatment with allergen-specific immunotherapy\n* Received 10 or more days of systemic steroids in the 3 months prior to study entry\n* Orofacial abnormalities that are likely to interfere with the subject's ability to take study treatment\n* Participated in another clinical study within the 3 months prior to study entry", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Months", "maximumAge": "30 Months", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Patrick Holt, MD", "affiliation": "Telethon Institute for Child Health Research", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Peter Sly, MD", "affiliation": "Telethon Institute for Child Health Research", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Mount Sinai School of Medicine", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Royal Children's Hospital", "city": "Melbourne", "state": "Victoria", "zip": "3052", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "Telethon Institute for Child Health Research", "city": "Perth", "state": "Western Australia", "zip": "6008", "country": "Australia", "geoPoint": {"lat": -31.95224, "lon": 115.8614}}]}, "referencesModule": {"references": [{"pmid": "16701145", "type": "BACKGROUND", "citation": "Mascarell L, Van Overtvelt L, Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am. 2006 May;26(2):283-306, vii-viii. doi: 10.1016/j.iac.2006.02.009."}, {"pmid": "16675331", "type": "BACKGROUND", "citation": "Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol. 2006 May;117(5):1047-53. doi: 10.1016/j.jaci.2005.12.1306. Epub 2006 Mar 6."}, {"pmid": "23768574", "type": "RESULT", "citation": "Holt PG, Sly PD, Sampson HA, Robinson P, Loh R, Lowenstein H, Calatroni A, Sayre P. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013 Oct;132(4):991-3.e1. doi: 10.1016/j.jaci.2013.04.049. Epub 2013 Jun 12. No abstract available."}], "seeAlsoLinks": [{"label": "Immune Tolerance Network (ITN) website", "url": "http://www.immunetolerance.org"}], "availIpds": [{"id": "SDY545", "type": "Individual Participant Data Set", "url": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY545", "comment": "ImmPort study identifier is SDY545."}, {"id": "SDY545", "type": "Study summary, -design with synopsis, -adverse events, -assessment, -medications, -demographics, -lab tests, -files, et al.", "url": "http://www.itntrialshare.org/project/Studies/ITN025ADPUBLIC/Study%20Data/begin.view?", "comment": "ImmPort study identifier is SDY545."}, {"id": "ITN025AD", "type": "Individual Participant Data Set", "url": "http://www.itntrialshare.org/project/Studies/ITN025ADPUBLIC/Study%20Data/begin.view?", "comment": "TrialShare is the ITN clinical trials research portal available to the public."}, {"id": "ITN025AD", "type": "Study overview with synopsis, -navigator, -schedule of events, -data and reports, biospecimens and availability.", "url": "http://www.itntrialshare.org/project/Studies/ITN025ADPUBLIC/Study%20Data/begin.view?", "comment": "TrialShare study identifier is ITN025AD."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Data access is provided to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "At a screening visit, subjects underwent procedures to establish that all inclusion criteria were met and none of the exclusion criteria were met. All guardians provided written informed consent", "recruitmentDetails": "Subject recruitment occurred between June 2006 and July 2007 at 2 sites in Australia and 1 site in the United States", "groups": [{"id": "FG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "FG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "26"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "BG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "51"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Aged 12-17 Months", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Aged 18-23 Months", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "28"}]}]}, {"title": "Aged 24-30 Months", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "25"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "26"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "43"}]}]}]}, {"title": "Severity of Atopic Dermatitis (AD) Using SCORAD Index", "description": "Scoring of Atopic Dermatitis (SCORAD) disease-severity scale measures intensity of erythema, edema/papulation, oozing/crusts, excoriations, lichenification and dryness, each on a scale from 0-3 for a maximum total of 18 points. This score is multiplied by 3.5 and added to 1/5 of the affected percent body surface area. The final score is added to the score from a 0-10 point pruritus visual analog scale (VAS) and a 0-10 point loss of sleep VAS. Summary: SCORAD (0-103)=extent (0-100)/5+intensity (0-18)x3.5 + pruritus and sleep (0-20).Interpretation: SCORAD (0 (no disease) to 103 (most severe)).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units on a Scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.3", "spread": "8.5"}, {"groupId": "BG001", "value": "11.4", "spread": "9.1"}, {"groupId": "BG002", "value": "12.3", "spread": "8.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion", "description": "Allergic sensitization is defined as a positive serum allergen specific Immunoglobulin E (IgE) CAP test\\[1\\] or a positive allergy skin prick test\\[2\\]. Not experiencing allergic sensitization is the better outcome for this measure.\n\n1. A positive serum allergen specific IgE CAP (ImmunoCAP) test result is defined by a result \\>= 0.35 kU/L. Higher scores indicate greater allergic sensitization.\n2. A positive skin prick test is defined as a wheal diameter that is 3 mm larger than that produced by a negative control. Higher wheal sizes indicate greater allergic reaction or sensitization.", "populationDescription": "Intent-to-treat minus one participant in placebo group who had a sibling in trial", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Three years (36 months) after Treatment Completion", "groups": [{"id": "OG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "OG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Participants who drop out (have missing efficacy endpoints) are considered treatment failures.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.28", "pValueComment": "Odds Ratios are calculated using a logistic regression with a Wald chi square test. Experimental group participants had a higher proportion of allergic sensitization than participants who received placebo", "statisticalMethod": "Chi-squared", "paramType": "Odds Ratio (OR)", "paramValue": "2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5", "ciUpperLimit": "10.5"}]}, {"type": "SECONDARY", "title": "Number of Participants With Current Asthma at Month 36 Status Post Treatment Completion", "description": "Participants who currently have asthma three years after end of treatment. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze. Current asthma is defined as a diagnosis of asthma and at least one episode of wheeze lasting 3 or more consecutive days in the past 12 months.", "populationDescription": "Intent-to-treat minus one participant in placebo group who had a sibling in trial", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Three years (36 months) after Treatment Completion", "groups": [{"id": "OG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "OG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Participants who drop out (have missing efficacy endpoints) are considered treatment failures.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.85", "pValueComment": "Odds Ratios are calculated using unadjusted exact logistic regression with mid p-value to adjust for the discreteness of the distribution", "statisticalMethod": "Chi-squared", "paramType": "Odds Ratio (OR)", "paramValue": "1.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "6.1"}]}, {"type": "SECONDARY", "title": "Time to First Onset of Asthma", "description": "Time to first onset of asthma is the time from the day a participant is randomized and initiates study treatment to the diagnosis of the first of three episodes of asthma. Asthma is defined as three distinct episodes of wheeze after the first year of life, each of which lasts 3 or more consecutive days and occurs in a clinical setting where asthma is likely and other likely conditions have been excluded. Episodes must be separated by at least 7 days without wheeze.", "populationDescription": "Intent-to-treat minus one participant in placebo group who had a sibling in trial", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Months", "timeFrame": "From Treatment Initiation to Month 36 Status Post Treatment Completion", "groups": [{"id": "OG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}, {"id": "OG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.0", "spread": "1.9"}, {"groupId": "OG001", "value": "38.3", "spread": "2.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.28", "pValueComment": "P-value is calculated using a log-rank test", "statisticalMethod": "Regression, Logistic", "paramType": "Hazard Ratio (HR)", "paramValue": "1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6", "ciUpperLimit": "5.6", "estimateComment": "Hazard ratio and 95% confidence intervals are calculated using an unadjusted Cox regression"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Start of study through three years post-treatment (up to four years total)", "description": "This study graded the severity of adverse events experienced by the study participant according to criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0 (June 10, 2003). One participant in the placebo group is included in adverse event reports, but excluded from further analysis.", "eventGroups": [{"id": "EG000", "title": "OMIP With Timothy Grass, Cat and House Dust Mite Allergens", "description": "Participants were administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months. OMIP consisted of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma.", "seriousNumAffected": 8, "seriousNumAtRisk": 25, "otherNumAffected": 25, "otherNumAtRisk": 25}, {"id": "EG001", "title": "Placebo", "description": "Participants were administered via the same route as the experimental group an oral placebo solution daily for 12 months. The placebo consisted of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL. After 12 months, treatment stopped and participants were tested 3 years after end of treatment for development of allergic sensitization and asthma.", "seriousNumAffected": 7, "seriousNumAtRisk": 26, "otherNumAffected": 26, "otherNumAtRisk": 26}], "seriousEvents": [{"term": "Conductive deafness", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Acute tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Breathing-related sleep disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Bronchial hyperreactivity", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Tonsillar hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}], "otherEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 26}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 8, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 20, "numAffected": 14, "numAtRisk": 26}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 12, "numAffected": 5, "numAtRisk": 26}]}, {"term": "Lacrimation increased", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 6, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 18, "numAffected": 8, "numAtRisk": 26}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 17, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 57, "numAffected": 21, "numAtRisk": 26}]}, {"term": "Oral pruritus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Teething", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 22, "numAffected": 8, "numAtRisk": 26}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 34, "numAffected": 15, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 52, "numAffected": 18, "numAtRisk": 26}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 60, "numAffected": 18, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 51, "numAffected": 19, "numAtRisk": 26}]}, {"term": "Allergy to animal", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 11, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 35, "numAffected": 9, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 20, "numAffected": 8, "numAtRisk": 26}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 7, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 14, "numAffected": 6, "numAtRisk": 26}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Croup infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 10, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 17, "numAffected": 6, "numAtRisk": 26}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 13, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 26, "numAffected": 12, "numAtRisk": 26}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 7, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 141, "numAffected": 21, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 145, "numAffected": 23, "numAtRisk": 26}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Otitis media acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 7, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 7, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 7, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 9, "numAffected": 5, "numAtRisk": 26}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 7, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 17, "numAffected": 7, "numAtRisk": 26}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 192, "numAffected": 22, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 184, "numAffected": 24, "numAtRisk": 26}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 6, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 26}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 12, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 26, "numAffected": 10, "numAtRisk": 26}]}, {"term": "Arthropod bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Febrile convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 11, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 8, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 10, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 111, "numAffected": 21, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 83, "numAffected": 20, "numAtRisk": 26}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 8, "numAffected": 3, "numAtRisk": 26}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 11, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 48, "numAffected": 12, "numAtRisk": 26}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 6, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 82, "numAffected": 20, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 99, "numAffected": 20, "numAtRisk": 26}]}, {"term": "Sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 11, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 20, "numAffected": 8, "numAtRisk": 26}]}, {"term": "Stridor", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Tonsillar hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 62, "numAffected": 11, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 31, "numAffected": 10, "numAtRisk": 26}]}, {"term": "Dermatitis diaper", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 11, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 12, "numAffected": 7, "numAtRisk": 26}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 4, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 8, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 26}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 9, "numAtRisk": 25}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 26}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "One participant in the placebo group could not be included in intent-to-treat analyses because a sibling was also in the study"}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director, Clinical Research Operations Program", "organization": "DAIT/NIAID", "email": "DAITClinicalTrialsGov@niaid.nih.gov", "phone": "301-594-7669"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Germany", "Sweden"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M7071", "name": "Dermatitis, Atopic", "relevance": "LOW"}, {"id": "M7067", "name": "Dermatitis", "relevance": "LOW"}, {"id": "M7655", "name": "Eczema", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M8636", "name": "Food Hypersensitivity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC17", "name": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000091369", "term": "Immunomodulating Agents"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M2853", "name": "Immunomodulating Agents", "asFound": "Phase II Study", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}